6533b838fe1ef96bd12a4873
RESEARCH PRODUCT
Polymorphonuclear leukocyte integrins in deep venous thrombosis
R. Lo PrestiFilippo FerraraMaria MontanaGregorio CaimiBaldassare Caninosubject
Male0301 basic medicineIntegrinsNeutrophilsmedicine.drug_classIntegrinCD11a030204 cardiovascular system & hematologyMonoclonal antibody03 medical and health scienceschemistry.chemical_compound0302 clinical medicinepolymorphonuclear leukocyte integrinmedicineHumansdeep venous thrombosiVenous ThrombosisbiologyCell adhesion moleculebusiness.industryhemic and immune systemsHematologyGeneral MedicineMiddle AgedN-Formylmethionine leucyl-phenylalaninemedicine.diseasePathophysiologyN-Formylmethionine Leucyl-PhenylalanineVenous thrombosis030104 developmental biologychemistryIntegrin alpha MImmunologybiology.proteinTetradecanoylphorbol AcetateFemalebusinesspolymorphonuclear leukocyte activationdescription
The polymorphonuclear leukocytes (PMN) have a role in the pathophysiology of deep venous thrombosis (DVT). We examined the phenotypical expression of PMN beta2-integrins (CD l l a, CDl l b, CD 11c) in a group of 19 subjects with leg DVT. PMN cells were incubated with fluorescent monoclonal antibodies against CD11a, CD11b, CD11c, and the evaluation was made by flow cytofluorimetry. The same integrins were determined after in vitro activation with 4-phorbol 12-myristate 13-acetate (PMA) and N-formylmethionyl-leucyl-phenylalanine (fMLP). In DVT subjects, at baseline, the phenotypical expression of CD11b was decreased and that of CD11c increased when compared with normal controls. In normal subjects PMN activation with PMA and fMLP led to a constant increase of all PMN adhesion molecules, while in DVT subjects the CDl l a did not show any change. These data might have therapeutical ap plications, especially with the aim of preventing post-thrombotic deterioration of vein function.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2005-01-29 |